Harnessing anticalin technology as a multi-targeted treament approach for vision loss

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1122132

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Development Grants

Funding Amount: $627,273.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Vision Science

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

diabetes | diabetic retinopathy | pre-clinical studies | targeted therapy | vision loss

Related Links